Kestra Medical Technologies financials
$28.29−0.60%
Close Sep 30, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY26 Apr 30 | FY25 Apr 30 |
|---|---|---|
| Revenue | $95.1M | $59.8M |
| Gross profit | $48.9M | $24.2M |
| Gross margin | 51.4% | 40.5% |
| Operating income | -$134.7M | -$106.4M |
| Net income | -$131.6M | -$126.1M |
| Net margin | −138.4% | −210.9% |
| Diluted EPS | $-2.43 | $-5.13 |
| EBITDA | -$126.0M | -$98.4M |
| Operating cash flow | -$81.7M | -$77.6M |
| Free cash flow | -$116.6M | -$100.5M |
| Diluted shares | 54.2M | 24.6M |
Balance sheet
| Period end | Apr 30 | Apr 30 |
|---|---|---|
| Cash & equivalents | $99.7M | $237.6M |
| Short-term investments | $96.7M | $0.00 |
| Total debt | $42.6M | $41.1M |
| Total assets | $358.5M | $295.7M |
| Total liabilities | $98.8M | $90.3M |
| Shareholders' equity | $259.7M | $205.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology